Targeting of RGD‐modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution studyAstrid J. Schraa, Grietje Molema, Johannes H. Proost et al.|International Journal of Cancer|2002Cited by 73
Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targetingAstrid J. Schraa, Grietje Molema, Agnes D. Berendsen et al.|Journal of Controlled Release|2002Cited by 64
Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseasesAstrid J. Schraa, Grietje Molema, Maaike Everts et al.|Biotechnology annual review|2002Cited by 18
RGD‐modified anti‐CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward α<sub>v</sub>β<sub>3</sub>‐expressing endothelial cellsAstrid J. Schraa, Grietje Molema, Robbert J. Kok et al.|International Journal of Cancer|2004Cited by 17
A possible role for spontaneous interleukin‐8 production by acute myeloid leukemic cells in angiogenesis related processes: Work in progressEveline S.J.M. de Bont, Willem A. Kamps, Elisabeth van Wering et al.|Medical and Pediatric Oncology|2001Cited by 16